Founded in 2022, Momed Biotech specializes in AI-aided drug discovery, leveraging its self-developed "MechGen" AI drug design platform to decode the mechanistic biology of target proteins. This proprietary technology significantly shortens new drug development cycles and enhances the success rate of AI-driven drug discovery, positioning the company at the forefront of transformative pharmaceutical R&D.

The inclusion of Momed Biotech in the "Seed Unicorn" list not only acknowledges its technological innovation but also solidifies its leading role in AI-driven drug development and precision medicine. As a key highlight of Zhejiang’s innovation ecosystem, the recognition underscores the company’s ability to bridge cutting-edge AI algorithms with biological insights, addressing critical challenges in modern drug discovery.

The Hangzhou Wanwu Shengzhang Conference, an annual flagship event for China’s innovation and entrepreneurship community, serves as a nexus for global tech leaders, visionary entrepreneurs, and investment authorities. Renowned as a "barometer for China’s innovative enterprises," this year’s conference zeroed in on hard technology sectors such as artificial intelligence, biomedicine, new energy, and semiconductors, aiming to identify high-potential emerging enterprises reshaping industries. Momed Biotech’s selection from the life sciences and health sector—one of only 20 enterprises in its field—spotlights its competitive edge in the AI-biomedicine crossover space.

This achievement not only demonstrates Hangzhou’s robust momentum in biomedical innovation but also validates the immense commercial promise of the "AI+biotechnology" intersection. By integrating machine learning with molecular biology, Momed Biotech is driving a paradigm shift in drug development, exemplifying how hard-tech startups can leverage interdisciplinary strengths to tackle unmet medical needs and redefine industry frontiers.‍